Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

89.06
+0.62000.70%
Post-market: 89.060.00000.00%19:30 EDT
Volume:818.97K
Turnover:72.74M
Market Cap:4.34B
PE:-20.60
High:89.81
Open:87.61
Low:86.99
Close:88.44
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:1.40
T/O Rate:2.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-339.81
PE(LYR):-23.50

Loading ...

Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial

MT Newswires Live
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Celcuity (CELC)

TIPRANKS
·
Jun 03

Celcuity plunges after experimental breast cancer treatment data disappoints

Reuters
·
Jun 03

Movement Alert|Celcuity Falls 23.24% in Regular Trading, Phase III VIKTORIA-1 Data Triggers Sell-the-News Reaction

Market Focus
·
Jun 03

Celcuity falls -22.2%

TIPRANKS
·
Jun 03

Celcuity reports efficacy, safety data from PIK3CA mutant cohort of VIKTORIA-1

TIPRANKS
·
Jun 02

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Moderna (MRNA) and Celcuity (CELC)

TIPRANKS
·
Jun 02

Celcuity Shares Fall 20.7% Premarket After Co Reports Late-Stage Data for Breast Cancer Drug

THOMSON REUTERS
·
Jun 02

Celcuity - Announces Phase 3 VIKTORIA-1 Trial Results For PIK3CA MT Cohort - SEC Filing

Reuters
·
Jun 02

Celcuity says Phase 3 VIKTORIA-1 shows gedatolisib combo halves progression or death risk vs alpelisib in PIK3CA-mutant breast cancer

Reuters
·
Jun 02

Celcuity - Gedatolisib-Triplet Shows Median Pfs of 11.1 Months VS 5.6 Months Compared to Alpelisib Plus Fulvestrant- SEC Filing

THOMSON REUTERS
·
Jun 02

Celcuity - FDA Grants Priority Review to Celcuity's Gedatolisib Nda; Pdufa Date July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 02

Celcuity - Announces Phase 3 Viktoria-1 Trial Results for Pik3CA Mt Cohort - SEC Filing

THOMSON REUTERS
·
Jun 02

Celcuity - Gedatolisib Regimens Generally Well Tolerated With Mostly Low-Grade Adverse Events - SEC Filing

THOMSON REUTERS
·
Jun 02

Celcuity - on Track for Gedatolisib Commercial Launch Pending FDA Approval in Q3 2026 - SEC Filing

THOMSON REUTERS
·
Jun 02

Celcuity to Hold Conference Call to Discuss Results for the Pik3CA Mutant Cohort of the Phase 3 Viktoria-1 Clinical Trial of Gedatolisib Regimens in Hr+/Her- Advanced Breast Cancer on June 2, 2026

THOMSON REUTERS
·
Jun 01

Stock Track | Celcuity Inc Soars 5.35% Intraday on Board Expansion and New Director Appointment

Stock Track
·
May 20

Celcuity amends 8-K to provide full text of amended Item 5.02 disclosures

Reuters
·
May 20

Celcuity shareholders approve 2026 stock incentive plan at annual meeting

Reuters
·
May 19

Celcuity Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 18